NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What unique warning is associated with DPP-4 inhibitors?

Risk of severe hypoglycemia
Increase in LDL cholesterol
Pancreatitis
Hepatic encephalopathy

The correct answer is: Pancreatitis

DPP-4 inhibitors are a class of medications used to treat type 2 diabetes by increasing the levels of incretin hormones in the body, which help lower blood sugar levels. One unique warning associated with DPP-4 inhibitors is pancreatitis. Pancreatitis is the inflammation of the pancreas and can be a serious condition that requires medical attention. Patients taking DPP-4 inhibitors should be monitored for signs and symptoms of pancreatitis, such as severe abdominal pain, nausea, and vomiting. It is important to educate patients about the symptoms of pancreatitis and to counsel them to seek medical help if they experience any of these symptoms while taking DPP-4 inhibitors. Among the other options: A. Risk of severe hypoglycemia is more commonly associated with insulin and sulfonylureas, not DPP-4 inhibitors. B. DPP-4 inhibitors are actually associated with a neutral effect on LDL cholesterol levels. D. Hepatic encephalopathy is typically associated with liver disease and not specifically linked to DPP-4 inhibitors.